Evidence map›Paper›PMID 41148421›Full record

ReviewDiscover nano2025

Microneedle-nanoparticle hybrid platforms for metabolic syndrome: advances in point-of-care diagnostics and transdermal therapeutics.

Jaewon Choi, Sanghyeok Jang, Seona Yu, Yu-Rim Ahn, Minse Kim, Hyungseok Lee, Hyun-Ouk Kim

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jaewon Choi *Division of Chemical Engineering and Bioengineering, College of Art, Culture and Engineering, Kangwon National University, Gangwon State, Chuncheon, 24341, Republic of Korea.
Sanghyeok Jang *Department of Smart Health Science and Technology, College of Engineering, Kangwon National University, Gangwon State, Chuncheon, 24341, Republic of Korea.
Seona Yu *Division of Chemical Engineering and Bioengineering, College of Art, Culture and Engineering, Kangwon National University, Gangwon State, Chuncheon, 24341, Republic of Korea.
Yu-Rim AhnDivision of Chemical Engineering and Bioengineering, College of Art, Culture and Engineering, Kangwon National University, Gangwon State, Chuncheon, 24341, Republic of Korea.
Minse KimDivision of Chemical Engineering and Bioengineering, College of Art, Culture and Engineering, Kangwon National University, Gangwon State, Chuncheon, 24341, Republic of Korea.
Hyungseok LeeDepartment of Smart Health Science and Technology, College of Engineering, Kangwon National University, Gangwon State, Chuncheon, 24341, Republic of Korea. ahl@kangwon.ac.kr.
Hyun-Ouk KimDivision of Chemical Engineering and Bioengineering, College of Art, Culture and Engineering, Kangwon National University, Gangwon State, Chuncheon, 24341, Republic of Korea. kimhoman@kangwon.ac.kr.

Funding

Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry RS-2025-02304688National Research Foundation of Korea RS-2024-00423107Regional Innovation System & Education (RISE) Glocal University 30 Project program 2025-RISE-10-002
6 · The paper itself

Abstract

Metabolic syndrome encompasses various conditions, including diabetes, obesity, and metabolic diseases. It is characterized by high blood sugar, abnormal cholesterol, and high blood pressure levels. Research has investigated combined methods using microneedles and nanoparticles for diagnosis and treatment to improve effectiveness while reducing harm to healthy tissues. This process allows potential improvements in diagnostic capabilities for detecting biomarkers associated with metabolic diseases. Using microneedles in conjunction with nanoparticles offers a promising avenue for advancements in metabolic disease management. With the potential for targeted and precise delivery of therapeutic agents, this integrated approach could revolutionize treatment strategies. Combining these technologies not only enhances the delivery and efficacy of existing treatments but also paves the way for new therapeutic modalities. The careful management and focused release of therapeutic agents made possible by this method could help create new treatment options that weren't possible before. As we learn more about this field, exploring the potential challenges and limitations associated with integrating microneedles and nanoparticles is crucial for metabolic diseases. Understanding these aspects is fundamental to guiding further advancement and ensuring the development of safe, effective, and patient-centric interventions.

Indexed as

Hybrid nanostructuresMetabolic syndrome therapyMicroneedle-based deliveryMinimally invasive systemsNanoparticle integrationPoint-of-care diagnosticsTransdermal drug administration

Identifiers

PMID41148421
PMCPMC12569312

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.